Literature DB >> 28694146

Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting.

Annamaria Mascolo1, Cristina Scavone2, Maurizio Sessa2, Gabriella di Mauro2, Daniela Cimmaruta2, Valentina Orlando3, Francesco Rossi2, Liberata Sportiello2, Annalisa Capuano2.   

Abstract

Causality assessment is a fundamental biomedical technique for the signal detection performed by Pharmacovigilance centers in a Spontaneous reporting system. Moreover, it is a crucial and important practice for detecting preventable adverse drug reactions. Among different methods for causality assessment, algorithms (such as the Naranjo, or Begaud Methods) seem for their operational procedure and easier applicability one of the most commonly used methods. With the upcoming of the new European Pharmacovigilance legislation including in the definition of the adverse event also effects resulting from abuse, misuse and medication error, all well-known preventable causes of ADRs, there was an emerging need to evaluate whether algorithms could fulfill this new definition. In this review, twenty-two algorithmic methods were identified and none of them seemed to fulfill perfectly the new criteria of adverse event although some of them come close. In fact, several issues were arisen in applying causality assessment algorithms to these new definitions as for example the impossibility to answer the rechallenge question in case of medication error or AEFI (Adverse Event Following Immunization). Moreover, the exact conditions at which events occurred, as for example dosage or mode of administration should be considered to better assess causality in conditions of abuse/overdose, or misuse as well as in conditions of lack of expected efficacy reports for biotechnological drugs and adverse event occurring after mixing of vaccines. Therefore, this review highlights the need of updating algorithmic methods to allow a perfect applicability in all possible clinical scenarios accordingly or not with the terms of marketing authorization.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Adverse drug reaction reporting system; Adverse event definition; Algorithmic method; Causality assessment; Pharmacovigilance legislation

Mesh:

Year:  2017        PMID: 28694146     DOI: 10.1016/j.phrs.2017.07.005

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  14 in total

1.  Healthcare personnel's experience of reporting adverse drug reactions in Baghdad city: cross-sectional study.

Authors:  Saad Abdulrahman Hussain; Ashwaq Nagemeldeen Abbas; Shah-Zanan Alaa Habeeb; Athraa Kareem Abd-Ali; Zainab Saad Abdulrahman
Journal:  Int J Clin Pharm       Date:  2019-06-25

2.  Drug-Related Hospital Admissions via the Department of Emergency Medicine: A Cross-Sectional Study From the Czech Republic.

Authors:  Zuzana Očovská; Martina Maříková; Jaromír Kočí; Jiří Vlček
Journal:  Front Pharmacol       Date:  2022-06-13       Impact factor: 5.988

3.  New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database.

Authors:  Maurizio Sessa; Morten Andersen
Journal:  BioDrugs       Date:  2021-02-20       Impact factor: 5.807

4.  Did the New Italian Law on Mandatory Vaccines Affect Adverse Event Following Immunization's Reporting? A Pharmacovigilance Study in Southern Italy.

Authors:  Cristina Scavone; Concetta Rafaniello; Simona Brusco; Michele Bertini; Enrica Menditto; Valentina Orlando; Ugo Trama; Liberata Sportiello; Francesco Rossi; Annalisa Capuano
Journal:  Front Pharmacol       Date:  2018-09-04       Impact factor: 5.810

Review 5.  Understanding adverse drug-related emergency department visits: development of a conceptual model through a systematic review.

Authors:  Abubakar Ibrahim Jatau; Zayyanu Shitu; Garba Mohammed Khalid; Ismaeel Yunusa; Ahmed Awaisu
Journal:  Ther Adv Drug Saf       Date:  2019-06-24

6.  Preventable Cases of Oral Anticoagulant-Induced Bleeding: Data From the Spontaneous Reporting System.

Authors:  Annamaria Mascolo; Rosanna Ruggiero; Maurizio Sessa; Cristina Scavone; Liberata Sportiello; Concetta Rafaniello; Francesco Rossi; Annalisa Capuano
Journal:  Front Pharmacol       Date:  2019-04-30       Impact factor: 5.810

7.  Multimorbidity patterns in chronic older patients, potentially inappropriate prescribing and adverse drug reactions: protocol of the multicentre prospective cohort study MoPIM.

Authors:  Marisa Baré; Susana Herranz; Rosa Jordana; Maria Queralt Gorgas; Sara Ortonobes; Daniel Sevilla; Elisabet De Jaime; Olatz Ibarra; Candelaria Martín
Journal:  BMJ Open       Date:  2020-01-26       Impact factor: 2.692

8.  Comparison of Long-Term Clinical Implications of Beta-Blockade in Patients With Obstructive Airway Diseases Exposed to Beta-Blockers With Different β1-Adrenoreceptor Selectivity: An Italian Population-Based Cohort Study.

Authors:  Maurizio Sessa; Annamaria Mascolo; Cristina Scavone; Ilaria Perone; Annalisa Di Giorgio; Michele Tari; Annamaria Fucile; Antonella De Angelis; Daniel Bech Rasmussen; Magnus Thorsten Jensen; Kristian Kragholm; Francesco Rossi; Annalisa Capuano; Liberata Sportiello
Journal:  Front Pharmacol       Date:  2018-10-25       Impact factor: 5.810

9.  Predictors of new oral anticoagulant drug initiation as opposed to warfarin in elderly adults: a retrospective observational study in Southern Italy.

Authors:  Francesca Guerriero; Valentina Orlando; Valeria Marina Monetti; Francesca Maria Colaccio; Maurizio Sessa; Cristina Scavone; Annalisa Capuano; Enrica Menditto
Journal:  Ther Clin Risk Manag       Date:  2018-10-08       Impact factor: 2.423

Review 10.  Adverse events of nucleos(t)ide analogues for chronic hepatitis B: a systematic review.

Authors:  Raquel Scherer de Fraga; Victor Van Vaisberg; Luiz Cláudio Alfaia Mendes; Flair José Carrilho; Suzane Kioko Ono
Journal:  J Gastroenterol       Date:  2020-03-17       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.